KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Capital Expenditures (2016 - 2025)

Vertex Pharmaceuticals has reported Capital Expenditures over the past 17 years, most recently at $149.4 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $149.4 million for Q4 2025, up 61.34% from a year ago — trailing twelve months through Dec 2025 was $437.6 million (up 46.99% YoY), and the annual figure for FY2025 was $437.6 million, up 46.99%.
  • Capital Expenditures for Q4 2025 was $149.4 million at Vertex Pharmaceuticals, up from $101.8 million in the prior quarter.
  • Over the last five years, Capital Expenditures for VRTX hit a ceiling of $149.4 million in Q4 2025 and a floor of $33.6 million in Q4 2022.
  • Median Capital Expenditures over the past 5 years was $60.7 million (2021), compared with a mean of $68.8 million.
  • Peak annual rise in Capital Expenditures hit 264.52% in 2021, while the deepest fall reached 70.02% in 2021.
  • Vertex Pharmaceuticals' Capital Expenditures stood at $61.8 million in 2021, then plummeted by 45.63% to $33.6 million in 2022, then surged by 72.92% to $58.1 million in 2023, then soared by 59.38% to $92.6 million in 2024, then soared by 61.34% to $149.4 million in 2025.
  • The last three reported values for Capital Expenditures were $149.4 million (Q4 2025), $101.8 million (Q3 2025), and $145.7 million (Q2 2025) per Business Quant data.